Published in:
01-06-2021 | Irritable Bowel Syndrome | Original Article
Enteric-Release Budesonide May Be Useful in the Management of Non-Responsive Celiac Disease
Authors:
Amelie Therrien, Jocelyn A. Silvester, Maureen M. Leonard, Daniel A. Leffler, Alessio Fasano, Ciaran P. Kelly
Published in:
Digestive Diseases and Sciences
|
Issue 6/2021
Login to get access
Abstract
Background
Non-responsive celiac disease (NRCD) has many aetiologies, including gluten exposure. Budesonide may be used for refractory celiac disease (RCD) and celiac crisis.
Aims
We reviewed the effectiveness of budesonide to induce clinical and histologic response in NRCD with villous atrophy (VA).
Methods
Case series of adult cases with NRCD and VA prescribed budesonide at two celiac centers. Clinical variables and mucosal recovery (i.e., normal villous architecture within 1 year of treatment) were evaluated.
Results
Forty-two cases [77% female, median age 45.0 (IQR 28.3–60.0) years] were included. Most common symptoms were diarrhea (64%) and abdominal pain (62%). Budesonide was initiated at 9 mg (83%) for a median duration of 16.0 weeks (IQR 6.8–25.0 weeks). In total, 57% exhibited a clinical response, positively associated with diarrhea (adjusted OR 6.08 95% CI 1.04–35.47) and negatively with fatigue (adjusted OR 0.18 95% CI 0.03–0.98). Clinical response was higher among those with dietitian counseling prior to budesonide (n = 29, 70 vs. 23%, p < 0.01). Mucosal recovery was observed in 11/24 with follow-up duodenal biopsies. There was no association between clinical response and mucosal recovery, and 79% of clinical responders had a symptomatic relapse. RCD (48%) and chronic gluten exposure (24%) were the main suspected aetiologies of NRCD. Most individuals without a clinical response subsequently received an IBS-related diagnosis.
Conclusions
Budesonide may be effective to induce clinical response in NRCD presenting with diarrhea and VA, but clinical recurrence and lack of mucosal recovery are frequent after tapering. Other diagnoses, including coexisting IBS, may be considered in non-responders to budesonide therapy.